

# **Strategic Planning for IT Support of Grant-funded Research II**

( <http://www.esp.org/rjr/briite-04.pdf> )

---

**Robert J. Robbins**  
**rrobbins@fhcrc.org**  
**(206) 667 4778**

# Strategic Planning for IT Support of Grant-funded Research II

**Where are we now and where should we be going?**

( <http://www.esp.org/rjr/briite-04.pdf> )

---

Robert J. Robbins  
rrobbins@fhcrc.org  
(206) 667 4778

# Strategic Planning for IT Support of Grant-funded Research II

Where are we now and where should we be going?  
**How do we get there & what might get in our way?**



( <http://www.esp.org/rjr/briite-04.pdf> )

---

Robert J. Robbins  
rrobbins@fhcrc.org  
(206) 667 4778

# Strategic Planning for IT Support of Grant-funded Research II

Where are we now and where should we be going?  
How do we get there & what might get in our way?

 ( <http://www.esp.org/rjr/briite-04.pdf> ) 

---

Robert J. Robbins  
rrobbins@fhcrc.org  
(206) 667 4778

# Topics

---

- STRATEGIC PLANNING

# Topics

---

- STRATEGIC PLANNING
- GOAL: Where should we be going?

# Topics

---

- STRATEGIC PLANNING
- GOAL: Where should we be going?
- START: Where are we now?

# Topics

---

- STRATEGIC PLANNING
- GOAL: Where should we be going?
- START: Where are we now?
- PATH: How do we get there from here?


# Topics

---

- STRATEGIC PLANNING
- GOAL: Where should we be going?
- START: Where are we now?
- PATH: How do we get there from here?
- SUMMARY: The role of BRIITE (& others)

# Strategic Planning

# Fourth-Box Thinking



# Fourth-Box Thinking

---

## **Example of important driving question:**

**Q:** What can be done to maximize the effectiveness of IT at the level of individual grants?

# Fourth-Box Thinking

---

## **Example of important driving question:**

**Q:** What can be done to maximize the effectiveness of IT at the level of individual grants?

**A:** That's a critical question. A case can be made for centralized support of distributed computing.

# GOAL

Where should we be going?

# Where are we going?

---

## **Goal:**

Make it possible for nearly all biomedical researchers to use advanced information technology in support of their research at a cost barely more than the marginal costs necessitated by the specifics of their research.

d

# Where are we going?

---

## Goal:

Make it possible for nearly all biomedical researchers to use advanced information technology in support of their research at a cost barely more than the marginal costs necessitated by the specifics of their research...

That is, make it all work like a word processor...

# Where are we going?

---

**Goal:**

**NOTA BENE:**

**Use at marginal cost** is really nothing more and nothing less than what is expected of any mature infrastructure.

That is, make it all work like a word processor...

# Where are we going?

---

We are trying to develop generic systems to provide a robust IT infrastructure that allows **use at marginal cost** for all grant-funded biomedical researchers.

The solution must **interoperate** across multiple investigators, multiple research programs, multiple institutions, and multiple communities.

The interoperation should extend to reasonable interactions with biochemistry and on to chemistry and with biophysics and on to physics and with ...

# Where are we going?

---

We are trying to develop generic systems to provide a robust IT infrastructure that allows use at marginal cost for all grant-funded biomedical researchers.

The solution must interoperate across multiple investigators, multiple research programs, multiple institutions, and multiple communities.

The interoperation should extend to reasonable interactions with biochemistry and on to chemistry and with b  
and with ...

**TALL ORDER...**

# START

Where are we now?

# Topics

---

- We recognize that the problem exists.
- Commitment to address the problem exists at many levels.
- Recent technological advances make a solution seem possible.
- And, we are enthusiastic...
- But...

# Topics

---

- But, we must remember that

# Topics

---

- But, we must remember that
  - wherever we are, we're late.

# Topics

---

- But, we must remember that
  - wherever we are, we're late.
  - whatever we've got, it isn't enough.

# Topics

---

- But, we must remember that
  - wherever we are, we're late.
  - whatever we've got, it isn't enough.
  - whatever we do, it will be wrong.

# Topics

---

- But, we must remember that
  - wherever we are, we're late.
  - whatever we've got, it isn't enough.
  - whatever we do, it will be wrong.
  - standards are important, both to have and to avoid.

# Topics

---

- But, we must remember that
  - wherever we are, we're late.
  - whatever we've got, it isn't enough.
  - whatever we do, it will be wrong.
  - standards are important, both to have and to avoid.
  - we are at risk of “light's better” approaches.

# Topics

---

- But, we must remember that
  - wherever we are, we're late.
  - whatever we've got, it isn't enough.
  - whatever we do, it will be wrong.
  - standards are important, both to have and to avoid.
  - we are at risk of “light's better” approaches.
  - there is no silver bullet (no one has all the answers).

# START


Wherever we are,  
we're late...

# Topics


---

- To stay competitive, biomedical research institutions must deploy IT effectively.
- Moore's Law constantly transforms IT (and everything else).
- Moore's Law divides all IT project time into three periods:
  - Too hard
  - Too expensive
  - Too late


# Moore's Law: *The Effect*




# Moore's Law: *The Effect*




# Moore's Law: *The Effect*




# Moore's Law: *The Effect*




# Moore's Law: *The Effect*




# Moore's Law: *The Effect*



# Moore's Law: *The Effect*




# Moore's Law: *The Effect*




# Cost (constant performance)


---




# Cost (constant performance)




# Cost (constant performance)



# Cost (constant performance)



# Cost (constant performance)



# We're Late

---

- Late is good: it motivates.
- Late is bad: it encourages “light’s better” thinking.

# We're Late

---

- Late is good: it motivates.
- Late is bad: it encourages “light’s better” thinking.

**REMEMBER:** A shortcut is often the quickest way to someplace you weren't going.

# START

Whatever we've got,  
it isn't enough...

Reality check:  
budgets

# Reality Check

---

## Resource Availability:

- Compared to the recent past, current government spending on biomedical information infrastructure is huge.

# Reality Check

---

## Resource Availability:

- Compared to the recent past, current government spending on biomedical information infrastructure is huge.
- Compared to what's needed, current government spending on bio-medical information infrastructure is tiny.

# Rhetorical Question

---

**Which is likely to be more complex:**

- identifying, documenting, and tracking the whereabouts of **all parcels** in transit in the UPS system at one time

# Rhetorical Question

---

## Which is likely to be more complex:

- identifying, documenting, and tracking the whereabouts of **all parcels** in transit in the UPS system at one time
- identifying, documenting, and tracking all data, all materials, and all equipment relevant to all aspects of all publicly funded biomedical research, in all fields and on all topics.

# Business Factoids

---

## Five years ago, United Parcel Service:

- used redundant multi-terabyte databases to track all packages in transit
- had 4,000 full-time employees dedicated to IT
- spent one billion dollars per year on IT
- had an income of 1.1 billion dollars, against revenues of 22.4 billion dollars

# Business Comparisons

Company	Revenues	IT Budget	Pct
Chase-Manhattan	16,431,000,000	1,800,000,000	10.95 %
AMR Corporation	17,753,000,000	1,368,000,000	7.71 %
Nation's Bank	17,509,000,000	1,130,000,000	6.45 %
Sprint	14,235,000,000	873,000,000	6.13 %
IBM	75,947,000,000	4,400,000,000	5.79 %
MCI	18,500,000,000	1,000,000,000	5.41 %
Microsoft	11,360,000,000	510,000,000	4.49 %
United Parcel	22,400,000,000	1,000,000,000	4.46 %
Bristol-Myers Squibb	15,065,000,000	440,000,000	2.92 %
Pfizer	11,306,000,000	300,000,000	2.65 %
Pacific Gas & Electric	10,000,000,000	250,000,000	2.50 %
Wal-Mart	104,859,000,000	550,000,000	0.52 %
K-Mart	31,437,000,000	130,000,000	0.41 %

# Federal Funding of Biomedical-IT

---

## Appropriate funding level:

- approx. 5-15% of research funding
- *i.e.*, **billions** of dollars per year

# Federal Funding of Biomedical-IT

---

## Appropriate funding level:

- approx. 5-15% of research funding
- *i.e.*, **billions** of dollars per year

### Seem high?

What percent of institutional operating budgets goes to other mature infrastructure?

# Federal Funding of Biomedical-IT

---

A

## **Warning:**

**Until more resources become available, finding true SOLUTIONS to biomedical-IT problems will be impossible.**

What percent of institutional operating budgets goes to other mature infrastructure?

Reality check:  
Inadequate technology  
&  
“light’s better” solutions

# Caution from the Past

---

## Scientific Database Management

### Final Report

edited by

James C. French, Anita K. Jones, and John L. Pfalz

Report of the Invitational NSF Workshop on

Scientific Database Management

12–13 March 1990

Charlottesville, Virginia

Anita K. Jones, Chairperson

Technical Report 90-21

August 1990

# Caution from the Past

---

## U Va Tech Reports:

- **CS-90-21**

J.C. French, A.K. Jones and J.L. Pfaltz, Scientific Database Management (Final Report), August 1990.

<ftp://ftp.cs.virginia.edu/pub/techreports/CS-90-21.ps.Z>

- **CS-90-22**

J.C. French, A.K. Jones and J.L. Pfaltz, Scientific Database Management (Panel Reports and Supporting Material), August 1990

<ftp://ftp.cs.virginia.edu/pub/techreports/CS-90-22.ps.Z>

# Caution from the Past

---

## Two major conclusions:

- The single unifying cry of the workshop is that existing data models are inadequate for science data needs. (p. 6)

# Caution from the Past

---

## Two major conclusions:

- The single unifying cry of the workshop is that existing data models are inadequate for science data needs. (p. 6)
- The data source dimension (e.g., single or multi-source), which is not generally mentioned in the database literature, may present the most fundamental challenge. (p. 3)

# Data Model Problems

# Topics

---

- Data-model problems

- No support for rapid schema change.

- No support for inter-database referential integrity.

- No support for tri-state logic.

- No support for object-identity ambiguity.

- And there's more...

# Topics

---

- Data-model problems

If existing data models are inadequate, then much of the power (and extensibility) of DBMSs are lost, because systems built on them are fundamentally kludges.

An information system built on a bad data model is like a house built on sand...

# Data Source Problems

# Topics

---

- Data-source problems

Biology is a small-instrument, multi-source science.

Integrating multi-source data is hard.

Consistency flows in the wrong direction.

GenBank is a false model.


# Source I

## *Basics*

# Single-instrument Science

instrument

researchers




data flow



# Single-instrument Science

instrument

researchers



# Single-instrument Science

instrument

researchers

## RIGHT WAY:

With single-source science, data is **MOST** consistent nearest the source, making integration unnecessary (but making the need for path documentation high).

data flow

← increasing data consistency →


# Multi-instrument Science

---

researchers

data resource(s)

researchers




# Multi-instrument Science

researchers

data resource(s)

researchers



# Multi-instrument Science

---

researchers

data resource(s)

researchers

**STOP – WRONG WAY:**

**With multi-source science, data is  
LEAST consistent nearest the source,  
making true integration difficult.**

data flow


increasing data consistency

# Multi-instrument Science

researchers

data resource(s)

researchers



**Extra complexity:**  
**Undocumented, uncoordinated local data exchange among producers**


# Multi-instrument Science

---

researchers

data resource(s)

researchers



**Extra complexity:**


**Data collected locally to meet local needs are not globally consistent - or even equivalent.**

# Multi-instrument Science

researchers

data resource(s)

researchers



**Extra complexity:**

**Multiple centralized resources may exist,  
meaning there is no authoritative source.**

# Source II

## *Scope*

# Data-source Scope Issues

---

## Problems occur at many levels:

- Integrating sequence data into GenBank
- Connecting GenBank with other genomic resources
- Connecting genomic data with other biological data
- Connecting all biological data with medical data
- Connecting all biomedical data with...

Reality check:  
“light’s better” solutions

# “Light’s better” Solutions

---

- GenBank provides a model for public biomedical databases
- LSIDs can serve as database keys
- True DB solutions are too hard; IR-like solutions are adequate.
- Perfection is the enemy of the good; what we need is a commitment to getting things done using an 80:20 approach.


# GenBank as a False Model

---

- Classic Kuhnian paradigm science
- Simple, unambiguous data type (string)
- Symbiotic relationship with publishers
- Sequences are things, not actions

# Syntactics vs. Semantics, I

---



# Syntactics vs. Semantics, I

---

A: If you call a dog's tail a leg, how many legs does a dog have?

B: Uh, five?

# Syntactics vs. Semantics, I

---

A: If you call a dog's tail a leg, how many legs does a dog have?

B: Uh, five?

A: Nope, four! Calling a tail a leg don't make it one.

# Syntactics vs. Semantics, II

---

A: If you use LSIDs as primary keys for biomedical databases, does that solve the problem of inter-database referential integrity.

B: Uh, maybe?

# Syntactics vs. Semantics, II

---

A: If you use LSIDs as primary keys for biomedical databases, does that solve the problem of inter-database referential integrity.

B: Uh, maybe?

A: **Nope! Calling an LSID a key don't make it one.**

Reality check:  
No silver bullet

# Data-source Solutions

---

## **Institutional Solutions:**

- Getting from RO1 science to international standards is too big a step
- We need solutions at the levels of research institution and research community.
- Biomedical research organizations need to provide coherent support for biomedical IT, just as they do for biomedical bench research.
- Integrating institutional solutions is feasible; integrating individual lab solutions is not.

# PATH

How do we get there from here?

# PATH Issues

---

- Multiple solutions require multiple paths.

# PATH Issues

---

- Multiple solutions require multiple paths.

And these paths should be followed by different actors, concerned with different scopes, acting at different scales...

# PATH Issues

---

- Multiple solutions require multiple paths.
- Multiple solutions require an over-arching architectural vision, informed by an appropriate level of conceptual abstraction.

# PATH Issues

---

- Multiple solutions require multiple paths.
- Multiple solutions require an over-arching

Combining an architectural vision with appropriate abstraction will be critical. The biggest challenge is that a truly open federated infrastructure will have to be context-free, and removing context removes most of the familiar guidelines for good design.

# PATH Issues

---

- Multiple solutions require multiple paths.
- Multiple solutions require an over-arching architectural vision, informed by an appropriate level of conceptual abstraction.
- Standards must be chosen wisely: enabling standards must be embraced, constraining standards rejected, and premature standards avoided.

# PATH Issues

---

- Multiple solutions require multiple paths.
- Multiple solutions require an over-arching architectural vision, informed by an appropriate level of conceptual abstraction.
- Standards must be chosen wisely: enabling standards must be embraced, constraining standards rejected, and premature standards avoided.
- **Unexpected change (in everything) must be assumed and accommodated.**

# PATH Issues

---

- We must track industry trends and plot a course that matches our efforts with the prevailing industry winds.

# PATH Issues

---


- We must track industry trends and plot a course that matches our efforts with the prevailing industry winds.

The biomedical research community cannot control the direction of IT research and development, but we can take advantage of it (and possibly influence it somewhat).


# *Standards*

# Bad Data-exchange Standard


---




# Bad Data-exchange Standard




# Good Data-exchange Standard




# Good Data-exchange Standard




# Good Data-exchange Standard



# Good Data-exchange Standard




# Good Data-exchange Standard




# *Industry Trends*

# Industry Trends


---




# Industry Trends




# Industry Trends




# Industry Trends




# Industry Trends




# Industry Trends




# Industry Trends



# Industry Trends



# Industry Trends



# Industry Trends

Transition point  
where technology

Evolution into the “commodity” space results in a demand for “appliance-like” solutions.

Note that appliances have “use at marginal cost” characteristics.

Users want  
more technology,  
better performance

Users want  
convenience,  
reliability, low cost

Level  
performance  
needed  
most


on.

---

—

→

# Industry Trends



Early adopters drive the technical capabilities of the system, forcing the bar of acceptable performance upward. However, at some point the bar stabilizes and late adopters come to dominate the market for (and hence the design of) technology products.

# SUMMARY

The role of BRIITE (& others)

# Location of solution components

---

**LABORATORY:** QA/QC; basic data management and analysis

**INSTITUTION:** Shared resources; basic storage & management; statistics and analysis support; digital publishing support;

**RES. COMMUNITY:** Information appliances; public data collections; analytical support

**FUNDING AGENCY:** Core grant support; caBIG; BISTI

**GLOBAL:** Identity management; authentication, authorization, auditing

# Slides:

---

**<http://www.esp.org/rjr/briite-04.pdf>**

**END**